SCHEMBL18700583

SCHEMBL18700583

CS(C)(C)CCOCn1ccc2c(Br)ccnc21

nearest known ligand 0.30

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.30
GAA P10253 1/20 0.30
SI P14410 1/20 0.30
MGAM2 Q2M2H8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18559451 0.84 FGFR1 (0.35)
SCHEMBL18638434 0.83
SCHEMBL101528 0.83 DGAT1 (0.40) MGAMGAASIMGAM2
SCHEMBL29514152 0.83 DGAT1 (0.40) MGAMGAASIMGAM2
SCHEMBL17400916 0.82 MGAM (0.30) MGAMGAASIMGAM2
SCHEMBL14377366 0.82 MGAM (0.30) MGAMGAASIMGAM2
SCHEMBL18584069 0.82
SCHEMBL18638502 0.81 PIM1 (0.32)
SCHEMBL18638705 0.81
SCHEMBL18638703 0.81 PRKCI (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-11578068-B2 Oxadiazole derivatives as Rho-Kinase Inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2023-02-14 US disclosed
US-20230043959-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE CORPORATION 2023-02-09 US disclosed
US-11332468-B2 Azaindole derivatives as Rho-kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2022-05-17 US disclosed
US-11214573-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-01-04 US disclosed
US-11147812-B2 Tyrosine analogues derivatives as Rho-kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2021-10-19 US disclosed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US disclosed
US-10954236-B2 Tyrosine amide derivatives as Rho-Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2021-03-23 US disclosed
US-20210023080-A1 TYROSINE ANALOGUES DERIVATIVES AS RHO-KINASE INHIBITORS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-01-28 US disclosed
US-20200392133-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-17 US disclosed
US-20200331912-A1 OXADIAZOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-10-22 US disclosed
US-10513522-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE CORPORATION (US) 2019-12-24 US disclosed
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 US disclosed
US-9999619-B2 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors INCYTE HOLDINGS CORPORATION (US) 2018-06-19 US disclosed
US-20170253598-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2017-09-07 US disclosed
US-20170246157-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE CORPORATION 2017-08-31 US disclosed
US-9611269-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE CORPORATION (US) 2017-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210023080-A1 TYROSINE ANALOGUES DERIVATIVES AS RHO-KINASE INHIBITORS ROCK1, ROCK2, RHOA MGAM 4027/4885GAA 1812/4885SI 3945/4885
US-11147812-B2 Tyrosine analogues derivatives as Rho-kinase inhibitors ROCK1, ROCK2, RHOA MGAM 4027/4885GAA 1812/4885SI 3945/4885
US-20200331912-A1 OXADIAZOLE DERIVATIVES AS RHO-KINASE INHIBITORS ROCK1, ROCK2, RHOA MGAM 4271/4885GAA 3251/4885SI 4351/4885
US-10513522-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors JAK1, JAK3, JAK2 MGAM 4018/4885GAA 2773/4885SI 4711/4885
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 MGAM 1995/4885GAA 1678/4885SI 709/4885
US-11332468-B2 Azaindole derivatives as Rho-kinase inhibitors ROCK1, ROCK2, RHOA MGAM 4295/4885GAA 2621/4885SI 4532/4885
US-11578068-B2 Oxadiazole derivatives as Rho-Kinase Inhibitors ROCK1, ROCK2, RHOA MGAM 4271/4885GAA 3251/4885SI 4351/4885
US-10954236-B2 Tyrosine amide derivatives as Rho-Kinase inhibitors ROCK1, ROCK2, CIT MGAM 3943/4885GAA 2242/4885SI 4335/4885
US-11214573-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors JAK1, JAK3, JAK2 MGAM 4018/4885GAA 2773/4885SI 4711/4885
US-20170253598-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 MGAM 4018/4885GAA 2773/4885SI 4711/4885
US-20200392133-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, RHOA MGAM 4295/4885GAA 2621/4885SI 4532/4885
US-20170246157-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS JAK1, JAK2, JAK3 MGAM 4840/4885GAA 3118/4885SI 4844/4885
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS ROCK1, ROCK2, RHOA MGAM 4444/4885GAA 2949/4885SI 4520/4885
US-20230043959-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS JAK1, JAK2, JAK3 MGAM 4856/4885GAA 3302/4885SI 4860/4885
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, CIT MGAM 3943/4885GAA 2242/4885SI 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.